CRISPR Therapeutics (CRSP +6.31%) is a pioneering biotech corporate, however it is not but a winning one. That is why its stocks are down quite thus far this 12 months.
There are many causes, even though, to be bullish at the inventory, no longer the least of which is its advanced money place. The corporate had just about $2 billion in money, money equivalents, and marketable securities on the finish of 2025.
Symbol supply: Getty Pictures.
That more or less cushion offers the corporate respiring room to ramp up gross sales of its most effective licensed gene-editing remedy, Casgevy, which is used as a one-time remedy for sickle mobile illness and transfusion-dependent beta thalassemia. Casgevy, priced at $2.2 million in keeping with remedy, had $116 million in 2025 gross sales, together with $54 million within the fourth quarter on my own, indicating its gross sales are accelerating. Nonetheless, the corporate misplaced $578.6 million final 12 months.
Casgevy is just the beginning
CRISPR gene-editing has the possible to treatment sufferers of illness, no longer simply deal with them. Casgevy has already proven it may be a useful treatment. The issue, for now, is that Casgevy could be very dear and treats just a small portion of the inhabitants.
Alternatively, CRISPR already has 5 different remedies in medical trials in its pipeline, together with the ones with a lot better markets. The biotech corporate’s sturdy money place offers it time to deliver a few of these remedies in the course of the approval procedure.
The 3 with the broadest promise are CXT310 and CXT320 for heart problems and CTX112 for quite a lot of cancers and autoimmune problems. CTX310 and CTX320 are “in vivo” gene-editing therapies, which means they’re designed to edit genes without delay within the frame. Each remedies goal to scale back the danger of center illness via reducing blood lipids within the liver.
These days’s Trade
(6.31%) $3.23
Present Worth
$54.45
Key Information Issues
Marketplace Cap
$4.9B
Day’s Vary
$51.09 – $54.72
52wk Vary
$33.03 – $78.48
Quantity
50K
Avg Vol
1.9M
Gross Margin
-653467.24%
CTX112, extra usually referred to as zugo-cel (quick for zugocaptagene geleucel), is CRISPR Therapeutics’ next-generation “off-the-shelf” (allogeneic) CAR T-cell remedy. It’s being examined on autoimmune problems equivalent to lupus and systemic sclerosis, two uncommon sicknesses, however it’s also observed as a possible remedy to regard B-cell cancers, the commonest form of blood cancers within the U.S.
